Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
about
Denosumab: A bone antiresorptive drugCost-utility of denosumab for the treatment of postmenopausal osteoporosis in SpainTreatment options for postmenopausal osteoporosis.A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model.High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.Osteoporosis in chronic inflammatory disease: the role of malnutrition.Stem cell therapy for osteoporosis.Orofacial adverse effects of biological agents.Management of osteoporosis of the oldest old.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.Artemisia annua extract prevents ovariectomy-induced bone loss by blocking receptor activator of nuclear factor kappa-B ligand-induced differentiation of osteoclasts.Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings.Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis
P2860
Q34980675-F24568D5-904F-4B62-A140-59630E484B35Q35087883-B5B64414-89CF-45EB-891B-35FE3F967F74Q36202821-6C9DF85B-E58C-4BD5-ABCD-D632DF1724BCQ36211427-FE4D38E3-B663-48D9-ACAF-DB5F505345CAQ37348766-05795EC0-FE71-43BA-BD09-74BA697D5B25Q37488814-8BBB33FB-23E0-48D3-8FD7-001CED7D432BQ38051265-8AF003D2-F39B-4FAC-87D7-A858A954F5B9Q38177180-107BFB44-8090-49D8-A737-8070CCB37421Q38213692-5E6C33A5-FED6-442C-BFE7-3098B9E6DEE0Q38229503-2CD59D8A-E333-4736-B70F-0505CFF097BEQ38611601-FC14C251-A252-4EED-8E76-27CF92C07C8CQ39143823-083AD224-7EEC-4C84-9101-3F3FCAA64335Q39296189-B50DB834-2E4F-4A09-8CCB-3F94B29D8975Q39961852-7FCFE949-D8D3-40C1-9FB3-163E114976AFQ40324652-DE5B874D-B708-472B-A5FC-758990FB2011Q47166692-2B2FCD14-B280-470C-928E-5C23CD86F6CBQ48117380-6025FB2C-446F-4C4E-88B0-DF3CE67BA72BQ53060269-E704E157-561F-4417-963A-8FE10E168F7FQ54404484-11687BF5-EE95-48CC-ACE2-C723CDCB622CQ57217564-5BFAE18D-5AFC-4729-B3D6-420C483CF79D
P2860
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@ast
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@en
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@nl
type
label
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@ast
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@en
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@nl
prefLabel
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@ast
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@en
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@nl
P2093
P2860
P3181
P356
P1476
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
@en
P2093
Athanasios D Anastasilakis
Chrysostomos D Anastasilakis
Konstantinos A Toulis
P2860
P304
P3181
P356
10.2147/TCRM.S24239
P407
P577
2012-06-19T00:00:00Z